Clinical trial · Interventional
Adaptive Pet Study
F Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Delivery of Adaptive Radiation Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the benefit of using positron emission tomography (PET) in addition to the standard (computed tomography) CT to plan radiation therapy for cancer treatment. The information from the PET-CT may allow the investigators to change the radiation plan or the delivery of the radiation to the tumor/tumor site such as the total dose of radiation or the size of the area to receive further radiation. Presently the use of PET scans to adjust radiation therapy during radiation treatment is not standard of care and is being investigated in this study.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers | — | UNRESOLVED | — |
| Head and Neck Cancers | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Lung and Esophagus Cancers | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET-CT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- PET-CT
- interventionNames
- Other: PET-CT
Primary outcomes (1)
- measure
- The number of subjects with benefit from an intra-treatment PET-CT
- timeFrame
- 3 years
- description
- This benefit lies in the potential to adapt the treatment plan based on an intratreatment PET-CT. This may also be of significant prognostic utility, at an early enough time point to potentially alter treatment accordingly.
Secondary outcomes (5)
- measure
- Locoregional control.
- timeFrame
- Day of intra treatment PET-CT/ approx 2-4 hours
- description
- This study will evaluate the prognostic value of intra-treatment functional imaging on clinical relevant tumor endpoints (i.e. locoregional control, freedom from distant metastases, and overall survival).Comparison of intra-treatment FDG-PET indices will identify two groups of responses: PET responses and PET non-responses, which will correlate with prognosis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically (histologically or cytologically) proven diagnosis of carcinoma * Patients with local or regional nodal disease are eligible. * Zubrod Performance Status 0, 1, or 2. * Age ≥ 18 * Negative serum pregnancy test for women of child bearing potential * Patient must sign study-specific informed consent prior to study entry. Exclusion Criteria: * No gross disease visible on imaging at the start of radiotherapy * Contraindication to PET * Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy) * Breast feeding
References
Publications (1)
- DERIVEDMowery YM, Vergalasova I, Rushing CN, Choudhury KR, Niedzwiecki D, Wu Q, Yoo DS, Das S, Wong TZ, Brizel DM. Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):969-976. doi: 10.1016/j.ijrobp.2020.08.029. Epub 2020 Aug 13. PMID 32800802